Showing results (61-70 of 83) with videos related to
Sort By:
Pageof 9
Tuberculosis and Respiratory Diseases|July 28, 2017
Review of Sarcoidosis in a Province of South Korea from 1996 to 2014Min-Seok Kim, Cheol-Kyu Park, Hong-Joon Shin, et al.Thoracic Cancer|January 15, 2016
Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancerHeejung Ban, Kyu-Sik Kim, In-Jae Oh, et al.Thoracic Cancer|July 8, 2016
Pulmonary sclerosing pneumocytoma mimicking lung cancer: Case report and review of the literatureJung-Hwan Lim, Nuri Lee, Dae-Woong Choi, et al.Thoracic Cancer|May 16, 2018
Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancerTae-Ok Kim, In-Jae Oh, Bo Gun Kho, et al.BMC Cancer|August 28, 2016
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trialIn-Jae Oh, Kyu-Sik Kim, Cheol-Kyu Park, et al.Thoracic Cancer|November 4, 2016
Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment responseHa Young Park, Hyung Joo Oh, Ki-Hyun Kim, et al.Journal of Thoracic Disease|October 18, 2016
Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancerHyung-Joo Oh, Ha-Young Park, Ki-Hyun Kim, et al.International Journal of Radiation Oncology, Biology, Physics|October 24, 2022
Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 TrialYong-Hyub Kim, Sung-Ja Ahn, Sung Ho Moon, et al.Translational Lung Cancer Research|September 12, 2022
Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trialCheol-Kyu Park, Hyung-Joo Oh, Seung Soo Yoo, et al.The Oncologist|March 11, 2022
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)Sanjay Popat, Te-Chun Hsia, Jen-Yu Hung, et al.Pageof 9